Umoja wa Ulaya - Kimalta - EMA (European Medicines Agency)

eurogenerics holdings b.v. - teriparatide - l-osteoporożi - homeostasi tal-kalċju - qutavina is indicated in adults. trattament ta 'l-osteoporożi f'nisa wara l-menopawża u fl-irġiel b'riskju akbar ta' ksur. in postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures have been demonstrated. trattament ta 'osteoporożi assoċjat ma sostnut sistemika terapija bi glukokortikojdi f'nisa u l-irġiel f'riskju akbar ta' ksur.

Umoja wa Ulaya - Kimalta - EMA (European Medicines Agency)

accord healthcare s.l.u. - teriparatide - l-osteoporożi - homeostasi tal-kalċju - sondelbay is indicated in adults. trattament ta 'l-osteoporożi f'nisa wara l-menopawża u fl-irġiel b'riskju akbar ta' ksur. in postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures have been demonstrated. trattament ta 'osteoporożi assoċjat ma sostnut sistemika terapija bi glukokortikojdi f'nisa u l-irġiel f'riskju akbar ta' ksur.

Umoja wa Ulaya - Kimalta - EMA (European Medicines Agency)

sun pharmaceutical industries europe b.v. - capecitabine - stomach neoplasms; breast neoplasms; colonic neoplasms; colorectal neoplasms - capecitabine - capecitabine huwa indikat għat-trattament awżiljarju ta 'pazjenti wara kirurġija ta' stadju iii (dukes 'stage-c) kanċer tal-kolon. capecitabine huwa indikat għat-trattament tal-kanċer metastatiku tal-kolorektum. capecitabine huwa indikat għall-kura preferita tal-kanċer gastriku avvanzat flimkien ma ' reġim ibbażat fuq il -. capecitabine flimkien ma 'docetaxel huwa indikat għall-kura ta' pazjenti b'lokalment avvanzat jew tal-kanċer tas-sider metastatiku wara l-falliment tal-kimoterapija ċitotossika. it-terapija ta 'qabel kellha tinkludi anthracycline. capecitabine huwa wkoll indikat bħala monoterapija għall-kura ta 'pazjenti b'lokalment avvanzat jew tal-kanċer tas-sider metastatiku wara l-falliment ta' taxanes u ta 'kors ta' kimoterapija li fihom jew li għalihom l-aktar anthracycline ma tkunx indikata t-terapija.

Umoja wa Ulaya - Kimalta - EMA (European Medicines Agency)

novartis europharm limited - travoprost - ocular hypertension; glaucoma, open-angle - ophthalmologicals, antiglaucoma preparations and miotics - tnaqqis ta 'pressjoni intraokulari elevata f'pazjenti adulti bi pressjoni għolja fl-għajn jew glawkoma b'angolu miftuħ (ara sezzjoni 5. tnaqqis ta ' pressjoni għolja f'pazjenti pedjatriċi b'età minn 3 snin sa < 18-il sena bi pressjoni għolja fl-għajn jew pedjatriċi glawkoma.

Umoja wa Ulaya - Kimalta - EMA (European Medicines Agency)

novartis europharm limited - nepafenac - pain, postoperative; ophthalmologic surgical procedures - oftalmoloġiċi - nevanac is indicated for: , prevention and treatment of postoperative pain and inflammation associated with cataract surgery;, reduction in the risk of postoperative macular oedema associated with cataract surgery in diabetic patients.

Umoja wa Ulaya - Kimalta - EMA (European Medicines Agency)

astrazeneca ab - osimertinib mesilate - karċinoma, pulmun mhux taċ-Ċellula Żgħira - aġenti antineoplastiċi oħra, inibituri tal-proteina kinase - tagrisso as monotherapy is indicated for:- the adjuvant treatment after complete tumour resection in adult patients with stage ib-iiia non-small cell lung cancer (nsclc) whose tumours have epidermal growth factor receptor (egfr) exon 19 deletions or exon 21 (l858r) substitution mutations- the first-line treatment of adult patients nsclc with activating egfr mutations. - the treatment of adult patients with locally advanced or metastatic egfr t790m mutation-positive nsclc. tagrisso as monotherapy is indicated for:- the adjuvant treatment after complete tumour resection in adult patients with stage ib-iiia non-small cell lung cancer (nsclc) whose tumours have epidermal growth factor receptor (egfr) exon 19 deletions or exon 21 (l858r) substitution mutations. - the first-line treatment of adult patients with locally advanced or metastatic nsclc with activating egfr mutations. - the treatment of adult patients with locally advanced or metastatic egfr t790m mutation-positive nsclc.

Umoja wa Ulaya - Kimalta - EMA (European Medicines Agency)

santen oy - latanoprost, netarsudil mesilate - glaucoma, open-angle; ocular hypertension - oftalmoloġiċi - roclanda is indicated for the reduction of elevated intraocular pressure (iop) in adult patients with primary open-angle glaucoma or ocular hypertension for whom monotherapy with a prostaglandin or netarsudil provides insufficient iop reduction.

Umoja wa Ulaya - Kimalta - EMA (European Medicines Agency)

leo pharma a/s - tralokinumab - dermatite, atopika - preparazzjonijiet oħra dermatoloġiċi - adtralza is indicated for the treatment of moderate to severe atopic dermatitis in adult and adolescent patients 12 years and older who are candidates for systemic therapy.

Umoja wa Ulaya - Kimalta - EMA (European Medicines Agency)

janssen-cilag international n.v.    - amivantamab - karċinoma, pulmun mhux taċ-Ċellula Żgħira - aġenti antineoplastiċi - rybrevant as monotherapy is indicated for treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with activating epidermal growth factor receptor (egfr) exon 20 insertion mutations, after failure of platinum-based chemotherapy.

Umoja wa Ulaya - Kimalta - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - paclitaxel - breast neoplasms; pancreatic neoplasms; carcinoma, non-small-cell lung - aġenti antineoplastiċi - bħala mediċina weħidha, abraxane hu indikat għall-kura ta ' kanċer metastatiku tas-sider f'pazjenti adulti li jkunu fallew l-kura tal-ewwel linja għall-mard metastatiku u li għalihom standard, terapija li jkun fiha anthracycline ma tkunx indikata. abraxane flimkien ma 'gemcitabine huwa indikat għall-kura tal-ewwel linja ta' pazjenti adulti b'kanċer metastatiku tal-adenokarċinoma tal-frixa. abraxane f'kombinazzjoni ma 'carboplatin huwa indikat għall-kura tal-ewwel linja ta taċ-ċelluli mhux żgħar tal-pulmun il-kanċer fil-pazjenti adulti li mhumiex kandidati għall-potenzjalment kurattiva-kirurġija u/jew terapija ta' radjazzjoni.